论文部分内容阅读
目的:观察奈达铂(NDP)联合吉西他滨(GEM)治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:48例晚期NSCLC患者,随机分成观察组和对照组。观察组采用NDP+GEM方案,对照组采用DDP+GEM方案。结果:观察组26例,有效率(RR)为34.6%(9/26);对照组22例,RR为27.3%(6/22),两组有效率的差异无统计学意义(P>0.05)。结论:NDP联合GEM方案治疗晚期非小细胞肺癌疗效较好,且消化道反应小,患者耐受性好。
Objective: To observe the clinical efficacy and adverse reactions of NDP combined with gemcitabine (GEM) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: 48 patients with advanced NSCLC were randomly divided into observation group and control group. The observation group was treated with NDP + GEM protocol and the control group with DDP + GEM protocol. Results: In the observation group of 26 cases, the effective rate (RR) was 34.6% (9/26). In the control group, the RR was 27.3% (6/22), with no significant difference between the two groups (P> 0.05 ). Conclusion: NDP combined with GEM regimen is effective in treating advanced non-small cell lung cancer with small gastrointestinal reaction and good patient tolerance.